Polatuzumab vedotin is a Monoclonal Antibody Conjugated owned by Genentech USA, and is involved in 37 clinical trials, of which 11 were completed, 22 are ongoing, and 4 are planned.
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis
Polatuzumab vedotin (RG-7596) is an anti-CD79b monoclonal antibody. Anti-CD79b is an antibody-drug conjugates (ADC) having a cytotoxic drug linked through specialized chemical linkers to antibodies. The linker systems are designed to be stable in the bloodstream and release the cell-killing agent once inside targeted cancer cells. The ADC targets and binds to specific receptors present on the surface of cells. It is absorbed by the cancer cells and the chemotherapy agent linked to the antibody is releases inside the cancer cells and destroys them.
The revenue for Polatuzumab vedotin is expected to reach a total of $30.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Polatuzumab vedotin NPV Report.
Polatuzumab vedotin Overview
Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody, acts as an anti-neoplastic agent. It is produced by mammalian Chinese hamster ovary (CHO) cells. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma that has progressed or returned after at least two prior therapies. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Polatuzumab vedotin (RG-7596) is under development for the treatment of hematologic malignancies including Burkitt lymphoma, non-Hodgkin's lymphoma, primary mediastinal B-cell lymphoma, primary cutaneous DLBCL, High-grade B-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma (B-Cell Hodgkin Lymphoma),thymic carcinoma and T-Cell lymphomas, T-cell/histiocyte-rich large-B-cell lymphoma, epstein-barr virus (EBV) + DLBCL, NOS, ALK+ large B-cell lymphoma, relapsed or refractory follicular lymphoma and previously untreated relapsed or refractory diffuse large B-cell lymphoma. The drug candidate is administered intravenously. It is an anti-CD79b antibody-drug conjugate (ADC) composed of the cytotoxic agent monomethyl auristatin E (MMAE) linked to an anti-CD79b monoclonal antibody targeting MMAE to B-cells through CD79b. It was also under development for mantle cell lymphoma and chronic lymphocytic leukemia.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Polatuzumab vedotin
|Highest Development Stage|